Similarly, an observational study of Chinese patients with HER2+ tumours reported that 27% of those with advanced disease did not receive trastuzumab at any time after diagnosis and 49% did not receive trastuzumab in the first-line setting [14]. This evidence concerns the gene ERBB2 and neoplasm.